柳生 茂希学内講師

専門領域 小児腫瘍学/細胞遺伝子治療
学会認定医
  • 日本小児科学会 小児科専門医
  • 日本血液学会 血液専門医
  • がん治療認定医機構 がん治療認定医

経歴

  • 平成12年3月

    京都府立医科大学医学部卒業

  • 平成12年4月

    京都府立医科大学附属病院 小児科研修医

  • 平成13年4月

    大津市民病院 小児科研修医、専攻医

  • 平成15年4月

    京都市立病院 小児科

  • 平成17年4月

    京都府立医科大学大学院医学研究科博士課程入学

  • 平成21年3月

    京都府立医科大学大学院医学専攻科博士課程修了

  • 平成21年4月

    京都府立与謝の海病院 小児科/京都府立医科大学小児科学教室 助教(併任)

  • 平成23年4月

    京都府立医科大学小児科学教室 助教

  • 平成25年2月

    Postdoctoral Associate, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA

  • 平成27年8月

    京都府立医科大学小児科学教室 助教

  • 平成31年4月

    京都府立医科大学小児科学内講師 現在に至る

受賞歴

  •  

    Merit Award, International Cancer Research Symposium of Training Plan for Oncology Professionals 2018

  •  

    Meritorious Abstract Travel Award, 18th Annual Meeting of American Society of Gene and Cell therapy, May 2015

  •  

    Global Grant Scholarship, The Rotary Foundation, October 2012

  •  

    Best Poster Award, 43rd Congress of the International Society of Paediatric Oncology, October 2011

所属学会

  • 日本小児科学会
  • 日本小児血液・がん学会
  • 日本血液学会
  • American Society of Gene and Cell Therapy

代表的論文

  1. Yagyu S, Mochizuki H, Yamashima K, Kubo H, Saito S, Tanaka M, Sakamoto K, Shimoi A, Nakazawa Y. Lymphodepleted non-human primate model for the assessment of acute on-target and off-target toxicity of human CAR-T cells. Clin Transl Immunol 2021 in press

  2. Hasegawa A, Saito A, Narimatsu S, Nakano S, Nagai M, Ohnota H, Inada Y, Morokawa H, Nakashima I, Morita D, Ide Y, Matsuda K, Tashiro H, Yagyu S, Tanaka M, Nakazawa Y. Mutated GM-CSF-based CAR T-cells targeting CD116/CD131 complexes exhibit enhanced anti-tumor effects against AML. Clin Transl Immunol 2021 in press

  3. Nakamura K, Yagyu S, Hirota S, Tomida A, Kondo M, Shigeura T, Hasegawa A, Tanaka M, Nakazawa Y. Autologous antigen-presenting cells efficiently expand piggyBac transposon chimeric antigen receptor T cells with predominant memory phenotype. Mol Ther Methods Clin Dev 2021 in press

  4. Kubo H, Yagyu S, Nakamura K, Yamashima K, Tomida A, Kikuchi K, Iehara T, Nakazawa Y, Hosoi H. Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcoma. Mol Ther Oncolytics 2021 in press

  5. Morokawa H, Yagyu S, Hasegawa A, Tanaka M, Saito S, Mochizuki H, Sakamoto K, Shimoi A, Nakazawa Y. Autologous non-human primate model for safety assessment of piggyBac transposon-mediated chimeric antigen receptor T cells on granulocyte-macrophage colony-stimulating factor receptor. Clin Transl Immunol. 2020 Nov 22;9(11):e1207.

  6. Yagyu S, Hoyos V, Del Bufalo F, Brenner MK. Multiple mechanisms determine the sensitivity of human-induced pluripotent stem cells to the inducible caspase-9 safety switch. Mol Ther Methods Clin Dev. 2016

  7. Hoyos V, Del Bufalo F, Yagyu S, Ando M, Dotti G, Suzuki M, Bouchier-Hayes L, Alemany R, Brenner MK. Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung Cancers. Mol Ther. 2015

  8. Yagyu S, Hoyos V, Del Bufalo F, Brenner MK. An Inducible Caspase-9 Suicide Gene to Improve the Safety of Therapy Using Human Induced Pluripotent Stem Cells. Mol Ther. 2015

  9. Ninomiya S, Narala N, Huye L, Yagyu S, Savoldo B, Dotti G, Heslop HE, Brenner MK, Rooney CM, Ramos CA. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood. 125: 3905-16. 2015

  10. Ando M, Hoyos V, Yagyu S, Tao W, Ramos CA, Dotti G, Brenner MK, Bouchier-Hayes L. Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity. Cancer Gene Ther. 21: 472-82. 2014

  11. Farzad L, Cerullo V, Yagyu S, Bertin T, Hemminki A, Rooney CM, Lee B, Suzuki M. Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy. Molecular Therapy - Oncolytics 1, 14008. 2014

  12. Yagyu S, Iehara T. MYCN Nonamplified Neuroblastoma: Detection of Tumor-Derived Cell-Free DNA in Serum for Predicting Prognosis of Neuroblastoma. Pediatric Cancer, Volume 4, Hayat, M.A. (Ed.), ISBN 978-94-007-6591-7, Springer Netherlands, DOI 10.1007/978-94-007-6591-7. 2013

  13. Yagyu S, Iehara T, Hosoi H. A Novel Diagnostic Tool for Therapy Stratification of Neuroblastoma: Preoperative Analysis of Tumor Biology Using Circulating Tumor-Released DNA in Serum. Neuroblastoma, Prof. Hiroyuki Shimada (Ed.), ISBN: 978-953-51-1128-3, InTech, DOI: 10.5772/55793. 2013

  14. Sugimoto T, Gotoh T, Yagyu S, Kuroda H, Iehara T, Hosoi H, Ohta S, Ohira M, Nakagawara A. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines. Cancer Lett. 331: 115-21. 2013

  15. Yagyu S, Iehara T, Gotoh T, Miyachi M, Katsumi Y, Kikuchi K, Tsuchiya K, Osone S, Kuroda H, Sugimoto T, Sawada T, Hosoi H. Preoperative analysis of 11q loss using circulating tumor-released DNA in serum: a novel diagnostic tool for therapy stratification of neuroblastoma. Cancer Lett. 309:185-9. 2011

  16. Yagyu S, Gotoh T, Iehara T, Miyachi M, Katsumi Y, Tsubai-Shimizu S, Kikuchi K, Tamura S, Tsuchiya K, Imamura T, Misawa-Furihata A, Sugimoto T, Sawada T, Hosoi H. Circulating methylated-DCR2 gene in serum as an indicator of prognosis and therapeutic efficacy in patients with MYCN nonamplified neuroblastoma. Clin Cancer Res. 14: 7011-9. 2008

  17. Yagyu S, Morimoto A, Kakazu N, Tamura S, Fujiki A, Nakase Y, Iehara T, Hosoi H, Kuroda H. Late appearance of a Philadelphia chromosome in a patient with therapy-related acute myeloid leukemia and high expression of EVI1. Cancer Genet Cytogenet. 180: 115-20. 2008

  18. Yagyu S, Kuroda H, Fujiki A, Tamura S, Iehara T, Morimoto A, Hosoi H, Sugimoto T, Imashuku S. Successful non-T-cell-depleted HLA-haploidentical 3-loci mismatched bone marrow transplantation. Eur J Haematol. 74: 529-32. 2005

  19. Okuda T, Takeda K, Fujita Y, Nishimura M, Yagyu S, Yoshida M, Akira S, Downing JR, Abe T. Biological characteristics of the leukemia-associated transcriptional factor AML1 disclosed by hematopoietic rescue of AML1-deficient embryonic stem cells by using a knock-in strategy. Mol Cell Biol. 20: 319-28. 2000